• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novocure wins FDA nod for pivotal pancreatic cancer trial

December 18, 2017 By Sarah Faulkner

NovocureThe FDA has given Novocure (NSDQ:NVCR) the green light to bring the company’s Tumor Treating Fields tech into a pivotal Phase III pancreatic cancer trial.

The 556-patient study is designed to assess the safety and efficacy of Novocure’s TTFields combined with nab-paclitaxel and gemcitabine as a front-line treatment for unresectable locally-advanced pancreatic cancer.

Panova III’s primary endpoint is overall survival, with secondary endpoints that include progression-free survival, local progression-free survival and objective response rate.

“Despite extensive clinical research, pancreatic cancer is the third leading cause of cancer death in the U.S. in 2017,” principal investigator Dr. Daniel Von Hoff said in prepared remarks. “Nearly all patients with pancreatic cancer are diagnosed when the tumors are no longer resectable. We must continue evaluating potential new treatments until we improve survival outcomes for patients with pancreatic cancer.”

Patients randomized to the experimental arm will use a TTFields delivery system tuned to 150 kHz for at least 18 hours a day until the disease progresses, according to St. Helier, N.J.-based Novocure.

In a Phase II trial of TTFields combined with nab-paclitaxel and gemcitabine, progression-free survival more than doubled in patients with advanced pancreatic cancer.

“Panova III is Novocure’s third Phase III pivotal trial beyond glioblastoma, demonstrating our commitment to developing TTFields as a treatment for a variety of solid tumors,” Dr. Eilon Kirson, chief science officer & head of R&D, added. “With the FDA IDE approval in hand, we are now working closely with trial sites and institutional review boards to open sites and enroll patients as quickly as possible.”

Novocure’s system delivers low-intensity, intermediate frequency, alternating electric fields, called ‘Tumor Treating Fields,’ to inhibit cancer cell replication.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Oncology, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: NovoCure

IN CASE YOU MISSED IT

  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS